Trial results

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

NCT07483801 on ClinicalTrials.gov · last registry update 2026-03-19

Registered but not yet open, with 112 participants planned. Due to report April 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Sponsor type

Other

Enrollment

112

Started

2026-03

Primary completion

2027-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio)

Conditions studied

Cardiovascular Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.